These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 29103159)

  • 21. Comparison and modelling of pegylated or unpegylated G-CSF schedules in CHOP-14 regimen of elderly patients with aggressive B-cell lymphoma.
    Zeynalova S; Ziepert M; Scholz M; Schirm S; Zwick C; Pfreundschuh M; Loeffler M;
    Ann Hematol; 2013 Dec; 92(12):1641-52. PubMed ID: 23892922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim.
    Kang KW; Lee BH; Jeon MJ; Yu ES; Kim DS; Lee SR; Sung HJ; Choi CW; Park Y; Kim BS
    Cancer Med; 2020 Sep; 9(17):6102-6110. PubMed ID: 32633471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group.
    Borchmann P; Haverkamp H; Diehl V; Cerny T; Markova J; Ho AD; Eich HT; Mueller-Hermelink HK; Kanz L; Greil R; Rank A; Paulus U; Smardova L; Huber C; Dörken B; Nerl C; Krause SW; Mueller RP; Fuchs M; Engert A
    J Clin Oncol; 2011 Nov; 29(32):4234-42. PubMed ID: 21990399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.
    Itoh K; Ohtsu T; Fukuda H; Sasaki Y; Ogura M; Morishima Y; Chou T; Aikawa K; Uike N; Mizorogi F; Ohno T; Ikeda S; Sai T; Taniwaki M; Kawano F; Niimi M; Hotta T; Shimoyama M; Tobinai K;
    Ann Oncol; 2002 Sep; 13(9):1347-55. PubMed ID: 12196359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study.
    Engert A; Bredenfeld H; Döhner H; Ho AD; Schmitz N; Berger D; Bacon P; Skacel T; Easton V; Diehl V
    Haematologica; 2006 Apr; 91(4):546-9. PubMed ID: 16585019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mobilization of peripheral blood progenitor cells following CHOP treatment combined with delayed granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma.
    Takano H; Sawada K; Sato N; Natoya A; Tarumi T; Hirayama S; Koizumi K; Takahashi TA; Sekiguchi S; Koike T
    Leuk Lymphoma; 1996 May; 21(5-6):473-8. PubMed ID: 9172813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is BEACOPP better than ABVD?
    Cheson BD
    Curr Hematol Malig Rep; 2007 Jul; 2(3):161-6. PubMed ID: 20425365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biweekly THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for intermediate- and high-grade non-Hodgkins's lymphoma.
    Niitsu N; Umeda M
    Leukemia; 1998 Sep; 12(9):1457-60. PubMed ID: 9737696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of rhG-CSF on infection complications and impaired function of neutrophils secondary to chemotherapy for non-Hodgkin's lymphoma. Hokkaido Study Group of Malignant Lymphoma, and rhG-CSF, Japan.
    Kuni-Eda Y; Okabe M; Kurosawa M; Maekawa I; Higuchi M; Kawamura M; Morioka M; Suzuki S; Ohmura T; Fujimoto N
    Leuk Lymphoma; 1995 Feb; 16(5-6):471-6. PubMed ID: 7540462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2).
    Yokoyama M; Kusano Y; Nishihara A; Inoue N; Nishimura N; Mishima Y; Terui Y; Nukada T; Nomura T; Hatake K
    Support Care Cancer; 2020 Feb; 28(2):571-579. PubMed ID: 31093770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Group.
    Smith GM; Child JA; Cullen MH; Bailey NP; Woodruffe CM; Fletcher J; Earl H; Barnard D
    Hematol Oncol; 1996 Dec; 14(4):193-201. PubMed ID: 9267465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial.
    Osby E; Hagberg H; Kvaløy S; Teerenhovi L; Anderson H; Cavallin-Stahl E; Holte H; Myhre J; Pertovaara H; Björkholm M;
    Blood; 2003 May; 101(10):3840-8. PubMed ID: 12531794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A pharmacokinetic model of filgrastim and pegfilgrastim application in normal mice and those with cyclophosphamide-induced granulocytopaenia.
    Scholz M; Ackermann M; Engel C; Emmrich F; Loeffler M; Kamprad M
    Cell Prolif; 2009 Dec; 42(6):813-22. PubMed ID: 19689472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia.
    Crawford J
    Semin Oncol; 2003 Aug; 30(4 Suppl 13):24-30. PubMed ID: 14508717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MOPP/ABV/CAD chemotherapy with and without recombinant human granulocyte-macrophage colony stimulating factor in untreated, unfavorable prognosis Hodgkin's disease.
    Riccardi A; Gobbi P; Danova M; Giordano M; Pieresca C; Bertoloni D; Brugnatelli S; Ascari E
    Haematologica; 1993; 78(1):44-8. PubMed ID: 7684012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COP-BLAM regimen combined with granulocyte colony-stimulating factor and high-grade non-Hodgkin's lymphoma.
    Niitsu N; Umeda M
    Eur J Haematol; 1995 Aug; 55(2):88-92. PubMed ID: 7543059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparison of Pegfilgrastim and Filgrastim for the Primary Prophylactic Effect for Preventing Febrile Neutropenia in Patients Undergoing Rituximab with Dose-adjusted EPOCH Chemotherapy].
    Kataoka T; Sakurashita H; Taogoshi T; Nishigakiuchi R; Murase T; Izumitani S; Saeki Y; Matsuo H
    Yakugaku Zasshi; 2019; 139(4):629-633. PubMed ID: 30930398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Model-based design of chemotherapeutic regimens that account for heterogeneity in leucopoenia.
    Scholz M; Engel C; Loeffler M;
    Br J Haematol; 2006 Mar; 132(6):723-35. PubMed ID: 16487172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
    Diehl V; Franklin J; Hasenclever D; Tesch H; Pfreundschuh M; Lathan B; Paulus U; Sieber M; Rueffer JU; Sextro M; Engert A; Wolf J; Hermann R; Holmer L; Stappert-Jahn U; Winnerlein-Trump E; Wulf G; Krause S; Glunz A; von Kalle K; Bischoff H; Haedicke C; Duehmke E; Georgii A; Loeffler M
    J Clin Oncol; 1998 Dec; 16(12):3810-21. PubMed ID: 9850026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin's lymphoma.
    Ganesan P; Rajendranath R; Kannan K; Radhakrishnan V; Ganesan TS; Udupa K; Lakshmipathy KM; Mahajan V; Sundersingh S; Rajaraman S; Krishnakumar R; Sagar TG
    Ann Oncol; 2015 Jun; 26(6):1170-1174. PubMed ID: 25701453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.